Saturday, February 23, 2013

WaPo Special Report: Biased Research, Big Profits


Peter Whoriskey's story -- As drug industry’s influence over research grows, so does the potential for bias -- starts with research on Avandia (in comparison with two other drugs) in which pretty much everyone had a financial connection with GSK:

Whether these ties altered the report on Avandia may be impossible for readers to know. But while sorting through the data from more than 4,000 patients, the investigators missed hints of a danger that, when fully realized four years later, would lead to Avandia’s virtual disappearance from the United States:

The drug raised the risk of heart attacks.

“If you looked closely at the data that was out there, you could see warning signs,” said Steven E. Nissen, a Cleveland Clinic cardiologist who issued one of the earliest warnings about the drug. “But they were overlooked.”

3 Comments:

  1. gaddeswarup said...

    Abi,
    This seems to be an award winning article
    http://www.cepr.net/index.php/blogs/beat-the-press/washington-post-gets-award-for-reporting-on-corrupt-pharma-practices

  2. gaddeswarup said...

    Check also this on the growing costs of heath care in USA (I have heard similar stories in India)
    http://www.interfluidity.com/v2/4013.html

  3. krishna yadav said...

    Really interesting article thanks for sharing this nice story. Check For variety of Clothes on G3 Fashions..

    http://www.g3fashions.in/women/sarees/net-sarees/1-15-109.html